Using 3D printing and CT guidance for treating thoracic cancer with radioactive seeds
Safety and Efficacy of 3D Printing Coplanar Template Combined With CT Guided Radioactive I-125 Seed Implantation in the Treatment of Thoracic Malignant Tumors
This study is testing if using 3D printing and CT scans can make it easier and more accurate to place radioactive seeds in patients with thoracic cancer to improve their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05351268 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a 3D-printed coplanar template combined with CT guidance to improve the accuracy of radioactive iodine-125 seed implantation for treating thoracic malignant tumors. The approach aims to simplify the procedure, reduce costs, and enhance the precision of needle placement during treatment. By utilizing 3D printing technology, the study seeks to optimize the treatment process and ensure that the therapeutic dose is effectively delivered to the target area. The study focuses on patients with specific eligibility criteria, including those with controlled metastasis and no severe underlying health issues.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a pathological diagnosis of thoracic malignant tumors, lesion diameter less than 7 cm, and controlled metastasis.
Not a fit: Patients with severe lung function impairment or extensive systemic metastasis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with thoracic cancer by enhancing the accuracy of brachytherapy.
How similar studies have performed: While the use of 3D printing in medical applications is gaining traction, this specific combination of 3D printing and CT guidance for radioactive seed implantation is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment. * No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment. * No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found. * There is a suitable puncture path, and the therapeutic dose is expected to be achieved. * KPS \> 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months. Exclusion Criteria: * Severe impairment of lung function (such as FEV1 \< 40% predicted value, FVC \< 50% predicted value, DLCO \< 40% predicted value). * High risk of skin invasion and ulceration at the puncture site before treatment. * There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor. * Pregnant women, lactating women and mentally ill patients. * The patient with poor compliance and unable to complete the treatment. * Other conditions of the researchers who think it is not suitable to participate in this clinical trial.
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Zhe Ji, M.D.
- Email: aschoff@163.com
- Phone: 008618710002823
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.